Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis.

Area of Science:

• Hematology
• Clinical Trials
• Oncology

Background:

• Confirming patient benefit via progression-free survival (PFS) in B-cell non-Hodgkin lymphoma (B-NHL) and multiple myeloma (MM) is challenging due to novel therapies.
• The U.S. Food and Drug Administration (FDA) recommends early endpoints for accelerated approval (AA) in randomized trials.
• Identifying reliable early surrogate endpoints for PFS is crucial for both clinical and regulatory purposes.

Purpose of the Study:

• To evaluate if the complete response rate (CRR) can serve as an early surrogate endpoint for PFS in B-cell malignancies.
• To assess the correlation between CRR and PFS across different B-cell hematologic malignancies.

Main Methods:

• A systematic literature search was conducted using PubMed and ClinicalTrials.gov.
• Data from randomized trials reporting both CRR and PFS were analyzed.
• Meta-regression analysis was employed to determine the correlation between CRR and PFS.

Main Results:

• A significant correlation was observed between CRR and PFS across the analyzed trials.
• High R-squared values indicated strong correlations: 0.822 for aggressive B-NHL, 0.941 for indolent N-NHL, and 0.492 for MM.
• The study identified 52 relevant trials after applying exclusion criteria.

Conclusions:

• The complete response rate (CRR) demonstrates potential as an early surrogate endpoint for progression-free survival (PFS).
• CRR can be considered a valid early surrogate endpoint for granting accelerated approval (AA) in B-cell non-Hodgkin lymphoma (B-NHL) and multiple myeloma (MM).
• This finding supports the use of CRR in future clinical trial designs and regulatory evaluations for these hematologic malignancies.